REFERENCES
- Alcindor T, Bridges KR. Sideroblastic anaemias. Br J Haematol 2002; 116(4)733–743, [PUBMED], [INFOTRIEVE]
- Altes A, Remacha AF, Sureda A, Martino R, Briones J, Canals C, Brunet S, Sierra J, Gimferrer E. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29(12)987–989, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Angelucci E, Muretto P, Lucarelli G, Ripalti M, Baronciani D, Erer B, Galimberti M, Giardini C, Gaziev D, Polchi P. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemic Patients. Blood 1997; 90(3)994–998, [PUBMED], [INFOTRIEVE]
- Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001; 1382(2)130–138, [CROSSREF]
- Giardina PJ, Grady RW. Chelation therapy in β-thalassemia: an optimistic update. Semin Hematol 2001; 38(4)360–366, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fischer R, Longo F, Engelhardt R, Piga A, Nielsen P. Monitoring iron overload by SQUID biomagnetic liver susceptometry. Proceedings of the 12th International Conference on Oral Chelation (ICOC), Santorini, Greece, July, 2002, 65–67
- Ishak K, Baptista A, Bianchi L, Callea F, de Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22(6)696–699, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med 2002; 136(9)667–672, [PUBMED], [INFOTRIEVE]
- Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996; 88(2)705–713, [PUBMED], [INFOTRIEVE]
- Wong C, Richardson DR. β-Thalassaemia: emergence of new and improved iron chelators for treatment. Int J Biochem Cell Biol 2003; 35(7)1144–1149, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone L1. Transfus Sci 2000; 23(3)221–223, [CROSSREF]
- Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, Ripalti M, Sodani P, Tomassoni S, Visani G, Lucarelli G. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002; 1001(1)17–21, [CROSSREF]
- Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103(9)361–364, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003; 121(1)187–189, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003; 121(6)938–948, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002; 360(9332)516–520, [PUBMED], [INFOTRIEVE], [CROSSREF]